Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Brief summary (registry, in English)

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 195
• From 9 Jan 2026 to the primary completion date, 13 Oct 2028
• 59 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (59)

Sites in registry order. Pick your city on the disease page to sort them by distance.